Carimune NF (human immune globulin intravenous) / CSL Behring - LARVOL DELTA

Serum Immunoglobulin Trough Levels Following Immunoglobulin Replacement Therapy in Obese and Non-obese Patients (AAAAI 2019) - " Data were collected from three studies, in which IgPro10 (Privigen®) or Carimune® (CSL Behring, Bern, Switzerland) were administered intravenously once every 3–4 weeks at 200−800 mg/kg bw, as previously individualized by their physicians. At similar IgG doses (g/kg bw), serum IgG trough levels in obese and non-obese PID patients are close, and we found no evidence of relevant difference in efficacy. Therefore, individualized dosing within the same ranges may be considered for both obese and non-obese patients."

Clinical

ATTEND: Autologous Transplant To End NMO Spectrum Disorder (clinicaltrials.gov) - P2/3; N=50; Recruiting; Sponsor: Northwestern University

New P2/3 trial